Kinase Inhibitors Market: By Product (Angiogenesis, m-TOR, BRAF and MEK, Bcr-Abl Tyrosine-Kinase (TKI), EGFR, PI3K, Aurora-Kinase Inhibitors, & Others), By End-User (Hospitals, Research Labs, & Others) & By Region-Forecast (2016-2021)
[Report Updated: 03-03-2016]


Related Topics: AstraZeneca , Boehringer Ingelheim

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Kinase
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email pdb@bioportfolio.co.uk.

Introduction

Kinase inhibitors are enzymes which selectively block the action of other enzymes, and help in regulation of the activity of other proteins and, the activities of cells. Globally, growing focus of pharmaceutical companies on R&D to come up with potential medicines for treatment of cancers, rise in the in aging population, and increasing incidence and frequency of various cancers are the prime growth drivers of global kinase inhibitors market. In addition, increase in adoption of kinase inhibitors for newer applications, and emerging economies such as China, India and others, will create new opportunities for global kinase inhibitors market. However, The research and development having higher cost, complex approvals processes, and stringent government policies are the key restraints for global kinase inhibitors market.

This report identifies the global kinase inhibitors market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global kinase inhibitors market.


Geographically North America dominated global kinase inhibitors market, and Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, growing incidence and prevalence of cancer patients and modernizing healthcare infrastructure in the developing nations such as China, and India in this region. Among all the end-users, hospital segment has the highest market share in global kinase inhibitors market.

This report segments global kinase inhibitors market on the basis of product, end-user, and regional market as follows:

Kinase Inhibitors Market, By Product: Angiogenesis Inhibitors, m-TOR Inhibitors, BRAF and MEK Inhibitors, Bcr-Abl Tyrosine-Kinase Inhibitors (TKI), EGFR Inhibitors, PI3K Inhibitors, Aurora-Kinase Inhibitors, and Others

The report has focused study on kinase inhibitors market by basis of end-user such as: Hospitals, Research Labs, and Others

This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the kinase inhibitors market. Some of the major companies’ profiles in detail are as follows:

Takeda Pharmaceutical Company Limited

Boehringer Ingelheim GmbH

AstraZeneca, Eisai Co., Ltd.

Bristol-Myers Squibb

Glaxo SmithKline

Table of Contents
for Kinase Inhibitors Market: By Product (Angiogenesis, m-TOR, BRAF and MEK, Bcr-Abl Tyrosine-Kinase (TKI), EGFR, PI3K, Aurora-Kinase Inhibitors, & Others), By End-User (Hospitals, Research Labs, & Others) & By Region-Forecast (2016-2021) [Report Updated: 03-03-2016]

  • 1. Kinase Inhibitors Market – Market Overview

    2. Executive Summary

    3. Market Landscape

    3.1. Market Share Analysis

    3.2. Comparative Analysis

    3.3. Product Benchmarking

    3.4. End User Profiling

    3.5. Top 5 Financials Analysis

    4. Kinase Inhibitors Market– Market Forces

    4.1. Drivers

    4.1.1. Growing focus of pharmaceutical companies on R&D to come up with potential medicines for treatment of cancers

    4.1.2. Rise in the in aging population

    4.1.3. Increasing incidence and frequency of various cancers

    4.2. Restraints

    4.2.1. The research and development having higher cost

    4.2.2. Complex approvals processes

    4.2.3. Stringent government policies

    4.3. Opportunities

    4.3.1. Emerging economies

    4.3.2. Increase in adoption of kinase inhibitors for newer applications

    4.4. Challenges

    4.5. Porter’s Five Forces Analysis

    4.5.1. Bargaining Power of Suppliers

    4.5.2. Bargaining Power of Buyers

    4.5.3. Threat of New Entrants

    4.5.4. Threat of Substitutes

    4.5.5. Degree of Competition

    5. Kinase Inhibitors Market, By Product

    5.1. Angiogenesis Inhibitors

    5.2. m-TOR Inhibitors

    5.3. BRAF and MEK Inhibitors

    5.4. Bcr-Abl Tyrosine-Kinase Inhibitors (TKI)

    5.5. EGFR Inhibitors

    5.6. PI3K Inhibitors

    5.7. Aurora-Kinase Inhibitors

    5.8. Others

    6. Kinase Inhibitors Market, By End-User

    6.1. Hospitals

    6.2. Research Labs

    6.3. Others

    7. Kinase Inhibitors Market, By Geography

    7.1. Europe

    7.1.1. Germany

    7.1.2. France

    7.1.3. Italy

    7.1.4. Spain

    7.1.5. Russia

    7.1.6. U.K.

    7.1.7. Rest of Europe

    7.2. Asia Pacific

    7.2.1. China

    7.2.2. India

    7.2.3. Japan

    7.2.4. South Korea

    7.2.5. Rest of Asia-Pacific

    7.3. North America

    7.3.1. U.S.

    7.3.2. Canada

    7.3.3. Mexico

    7.4. Rest of the World (RoW)

    7.4.1. Brazil

    7.4.2. Rest of RoW

    8. Kinase Inhibitors – Market Entropy

    8.1. Expansion

    8.2. Technological Developments

    8.3. Merger & Acquisitions, and Joint Ventures

    8.4. Supply- Contract

    9. Company Profiles

    9.1. Takeda Pharmaceutical Company Limited

    9.2. Boehringer Ingelheim GmbH

    9.3. AstraZeneca, Eisai Co., Ltd.

    9.4. Bristol-Myers Squibb

    9.5. Glaxo SmithKline

    9.6. Incyte Corporation

    9.7. Bayer AG

    9.8. Pfizer Inc.

    9.9. Eisai Co., Ltd.

    9.10. Novartis AG

    *More than 40 Companies are profiled in this Research Report, Complete List available on Request*

    "*Financials would be provided on a best efforts basis for private companies"

    10. Appendix

    10.1. Abbreviations

    10.2. Sources

    10.3. Research Methodology

    10.4. Expert Insights

List Of Tables
in Kinase Inhibitors Market: By Product (Angiogenesis, m-TOR, BRAF and MEK, Bcr-Abl Tyrosine-Kinase (TKI), EGFR, PI3K, Aurora-Kinase Inhibitors, & Others), By End-User (Hospitals, Research Labs, & Others) & By Region-Forecast (2016-2021) [Report Updated: 03-03-2016]

No

Additional Details

Publisher

Publisher Information

Reference

80267 | HCR 0236

Report Format

PDF

 Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Pipeline Review, H2 2018
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Pipeline Review, H2 2018SummaryA...
20 Nov 2018 by Global Markets Direct USD $3,500 More Info
Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Pipeline Review, H2 2018
Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Pipeline Review, H...
20 Nov 2018 by Global Markets Direct USD $3,500 More Info
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipeline Review, H2 2018
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipe...
20 Nov 2018 by Global Markets Direct USD $3,500 More Info
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2018
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division ...
20 Nov 2018 by Global Markets Direct USD $3,500 More Info
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Pipeline Review, H2 2018
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Pipeline Review, H2 ...
20 Nov 2018 by Global Markets Direct USD $3,500 More Info
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Review, H2 2018
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Tra...
20 Nov 2018 by Global Markets Direct USD $3,500 More Info
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2...
20 Nov 2018 by Global Markets Direct USD $3,500 More Info
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemi...
26 Oct 2016 by Global Markets Direct USD $3,500 More Info
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2016
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or E...
26 Oct 2016 by Global Markets Direct USD $3,500 More Info
Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation
Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-C...
01 Aug 2016 by GBI Research USD $6,995 More Info

We Stock...